Trial Profile
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Feb 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Docetaxel
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CheckMate057
- Sponsors Bristol-Myers Squibb
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 18 May 2022 Data from this study used to assess the implications of different waning methods used in past National Institute for Health and Care Excellence (NICE) technology appraisals (TA) for predicted survival (life years (LYs)) presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 28 Feb 2022 Status changed from active, no longer recruiting to completed.